Cost-Effectiveness Of Pembrolizumab As First-Line Treatment Of Locally Advanced Or Metastatic Urothelial Carcinoma Ineligible For Cisplatin-Based Therapy In The United States.
JOURNAL OF CLINICAL ONCOLOGY(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要